This article seeks to provide the practising clinician with guidance on the pharmacological management of tic disorders in children and adults. We performed a systematic review of the literature on the treatment of tic disorders. A multi-institutional group of 14 experts in psychiatry, child psychiatry, neurology, pediatrics, and psychology engaged in a consensus meeting. The evidence was presented and discussed, and nominal group techniques were employed to arrive at consensus on recommendations. A strong recommendation is made when the benefits of treatment clearly outweigh the risks and burdens, and can apply to most patients in most circumstances without reservation. With a weak recommendation, the benefits, risks, and burdens are more closely balanced, and the best action may differ depending on the circumstances. Based on these principles, weak recommendations were made for the use of pimozide, haloperidol, fluphenazine, metoclopramide (children only), risperidone, aripiprazole, olanzapine, quetiapine, ziprasidone, topiramate, baclofen (children only), botulinum toxin injections, tetrabenazine, and cannabinoids (adults only). Strong recommendations were made for the use of clonidine and guanfacine (children only). While the evidence supports the efficacy of many of the antipsychotics for the treatment of tics, the high rates of side effects associated with these medications resulted in only weak recommendations for these drugs. In situations where tics are not severe or disabling, the use of a medication with only a weak recommendation is not warranted. However, when tics are more distressing and interfering, the need for tic suppression to improve quality of life is stronger, and patients and clinicians may be more willing to accept the risks of pharmacotherapy.
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Cet article cherche à offrir au clinicien un guide sur la prise en charge pharmacologique des désordres de tic chez les enfants et les adultes. Nous avons effectué une revue systématique de la littérature sur le traitement des troubles de tics. Un groupe multiinstitutionnel de 14 experts en psychiatrie, en pédopsychiatrie, en neurologie, en pédiatrie et en psychologie a tenu une réunion de consensus. Les données probantes ont été présentées et discutées, et des techniques de groupe nominal ont été employées afin de parvenir à un consensus à propos des recommandations. Une recommandation ferme • Weak recommendations are made for the use of pimozide, haloperidol, fluphenazine, metoclopramide (children only), risperidone, aripiprazole, olanzapine, quetiapine, ziprasidone, topiramate, baclofen (children only), botulinum toxin injections, tetrabenazine, and cannabinoids (adults only) for the treatment of tics.
• Strong recommendations were made for the use of clonidine and guanfacine (children only) for the treatment of tics.
• While the evidence supports the efficacy of many of the antipsychotics for the treatment of tics, the high rates of side effects associated with these medications resulted in only weak recommendations for these drugs.
T ic disorders, including Tourette syndrome, are common, childhood-onset, neuropsychiatric disorders of variable severity and favourable prognosis for improvement by adulthood. In many people, treatment, other than education, is not needed. If tics become severe or disabling, patients may choose medical or behavioural therapy.
Antipsychotics are the oldest and most effective medications for the treatment of tics, but they have many undesirable side effects, including EPSs, 1,2 effects on prolactin, 1 metabolic effects, such as weight gain and elevation of cholesterol, 1 sedation, and prolongation of the QT interval on EKG. 3 These side effects have prompted clinicians to search for other treatments.
This article seeks to provide the practising clinician with guidance on the pharmacological management of tic disorders in children and adults. There are 2 primary clinical questions addressed in this guideline: Which medications are effective in suppressing tics? What are the benefits and harms of these medications?
Methods

Search Strategy and Data Extraction
We performed a systematic review of the literature on the treatment of tic disorders. We included systematic reviews, RCTs, and prospective open-label studies on the treatment of tics in children or adults. When this type of evidence was not available, we searched for retrospective case series. The primary outcome assessed for this review was the treatment effect on tics as measured using validated scales, such as the YGTSS. Secondary outcomes included EPSs, sedation, metabolic side effects, and EKG changes.
To find relevant articles, we searched the MEDLINE (1950 to October 2010) and EMBASE (1980 to October 2010) databases using highly sensitive search strategies for clinical trials on the treatment of tics (online eAppendix 1 for MEDLINE search strategy). Abstracts retrieved from the searches were reviewed independently by 2 authors for relevant articles. Full text articles were then read in detail to determine whether inclusion criteria were fulfilled. Data were extracted independently by 2 authors from the included studies and entered into pre-designed summary est faite lorsque les avantages du traitement l'emportent nettement sur les risques et le fardeau de la maladie, et qu'elle peut s'appliquer sans réserve à la plupart des patients dans presque toutes les circonstances. Dans le cas d'une recommandation faible, les avantages, risques et le fardeau de la maladie sont dans un équilibre plus rapproché, et la meilleure mesure à prendre peut différer selon les circonstances. D'après ces principes, des recommandations faibles ont été faites pour l'utilisation des médicaments suivants : pimozide, halopéridol, fluphénazine, métoclopramide (pour enfants seulement), rispéridone, aripiprazole, olanzapine, quétiapine, ziprasidone, topiramate, baclofen (pour enfants seulement), injections de toxine botulinique, tétrabénazine, et cannabinoïdes (pour adultes seulement). Des recommandations fermes ont été faites pour l'utilisation de la clonidine et de la guanfacine (pour enfants seulement). Bien que les données probantes appuient l'efficacité de nombreux antipsychotiques pour le traitement des tics, les taux élevés d'effets secondaires associés à ces médicaments n'ont amené que des recommandations faibles pour ces médicaments. Dans les cas où les tics ne sont pas graves ou incapacitants, l'utilisation d'un médicament qui n'a qu'une faible recommandation n'est pas indiquée. Cependant, lorsque les tics causent plus de détresse et de perturbations , le besoin de supprimer les tics pour améliorer la qualité de vie est plus pressant, et patients et cliniciens peuvent être plus disposés à accepter les risques de la pharmacothérapie.
forms. These forms were developed to ensure completeness and consistency of the extracted data, and the 2 authors' forms were compared for accuracy. If the studies reported common outcome measures, meta-analysis of study results was attempted. For prospective observational studies, we reported the difference in means and 95% confidence intervals between baseline and end point evaluations of tic severity.
Procedures for Evaluating the Evidence and Developing Recommendations
RCTs were evaluated for methodological quality using quality criteria developed by the USPSTF (online eAppendix 2). 4 Systematic reviews were evaluated for methodological quality using the AMSTAR tool. 5 Two authors independently assessed methodological quality for each included RCT and systematic review. Based on the fulfillment of USPSTF quality criteria, individual RCTs were rated as good, fair, or poor. Systematic reviews were given an AMSTAR score of 0 to 11 points. We subsequently graded the body of evidence for each medication as high, moderate, low, or very low, based on the GRADE system 6 (online eAppendix 3).
A classification scheme based on the GRADE system was also used to make recommendations for the treatment of tics (Table 1) . A strong recommendation is made when the benefits of treatment clearly outweigh the risks and burdens, and can apply to most patients in most circumstances without reservation. With a weak recommendation, the benefits, risks, and burdens are more closely balanced, and the best action may differ depending on circumstances. We created a third category, Category X, for medications where insufficient evidence exists to make a formal recommendation. A multi-institutional group of 14 experts in psychiatry, child psychiatry, neurology, pediatrics, and psychology engaged in a consensus meeting. The consensus group did not receive any industry sponsorship and developed this manuscript independently, with no restrictions of any kind. The evidence was presented and discussed, and nominal group techniques were employed to arrive at consensus on recommendations. The consensus group considered the evidence both in adults and in youth, and, unless otherwise specified, recommendations apply to both age groups.
Stakeholder Involvement
The consensus group included 3 people from the Tourette Syndrome Foundation of Canada, whose role was to represent the interests of patients and families affected by tic disorders. Before the consensus group meeting, a needs assessment was performed through an anonymous survey of Canadian physicians. This needs assessments evaluated preferences on guideline content and dissemination materials, and was incorporated into the overall plan for the guideline project.
Results
The combined MEDLINE and EMBASE searches yielded 1924 abstracts. Among these, 167 were chosen for full text review. Sixty-three studies met inclusion criteria. They comprised 52 studies and 1 systematic review on the pharmacological treatment of tics, 1 evidence-based review, and 3 studies on behavioural interventions, 3 studies on deep brain stimulation, and 3 studies on transcranial magnetic stimulation (online eAppendix 4). The studies on nonpharmacological treatment modalities are described in the companion article in this In Review. 7 Studies performed before 1990 used a wide variety of outcome measures for the measurement of tic severity, and frequently used crossover study designs, with poor reporting of results. Therefore, we were unable to perform a metaanalysis of study results for most medications. Most studies performed after 1990 used the YGTSS as the measure of tic severity. A decrease in the YGTSS total tic score of 8 points (out of 50) is considered clinically meaningful.
Antipsychotics for the Treatment of Tics
Online eAppendix 5 lists all included trials of antipsychotics, and Table 2 summarizes recommendations and suggested dosage ranges.
Pimozide. Six RCTs have been conducted on the use of pimozide for tics. [8] [9] [10] [11] [12] [13] These trials were included in a recent Cochrane systematic review 14 that received an AMSTAR score of 9 (out of 11). A meta-analysis of study results was not possible because of methodological concerns and clinical heterogeneity.
The 6 RCTs included a total of 162 participants, aged 7 to 53 years. Mean dosages of pimozide ranged from 2.4 to 12.0 mg/day. Pimozide was compared with placebo alone, 8 haloperidol alone, 13 both placebo and haloperidol, 9, 12 and risperidone. 10, 11 The methodological quality of each of the 6 RCTs was fair. Pimozide was superior to placebo in all 3 RCTs. In comparison to haloperidol, pimozide showed similar efficacy in 2 RCTs (both treatments improved tics) and was inferior in 1. There was no significant difference between pimozide and risperidone in total tic scores in 2 RCTs, with both drugs showing benefit. The magnitude of improvement in tics in all studies was clinically important.
Haloperidol was associated with more EPSs than pimozide, while pimozide was associated with more EPSs than placebo. QTc intervals were significantly prolonged by pimozide, but not by haloperidol or placebo.
Recommendation Grade for Pimozide: Weak Recommendation, High-Quality Evidence. While there is high-quality evidence that pimozide is effective in the treatment of tics, our consensus group has made a weak recommendation based on the risk-benefit profile of this medication. Treatment with pimozide requires monitoring for EPSs and of EKGs for QT interval prolongation. Clinicians within our consensus group use lower dosages of pimozide than used in the RCTs, and do not recommend using more than 6 mg/day.
Haloperidol. Five studies have assessed haloperidol for tics; 2 fair-quality RCTs compared haloperidol with pimozide and placebo, 9, 12 and 1 fair-quality RCT compared haloperidol with pimozide. 13 In addition, 2 single-blind, placebo-controlled, crossover studies compared haloperidol with other medications; 1 compared haloperidol with 15 and the other compared haloperidol with trifluoperazine, fluphenazine, and placebo. 15 The 5 studies included a total of 113 patients, aged 7 to 46 years. Dosages of haloperidol ranged from 2.5 to 20 mg/day. All studies reported clinically meaningful improvement in tics with haloperidol, relative to baseline and compared with placebo. Conversely, all studies reported higher rates of sedation, lethargy, and EPSs with haloperidol than with other medications and placebo.
Recommendation Grade for Haloperidol: Weak Recommendation, High-Quality Evidence. While there is highquality evidence that haloperidol is effective in the treatment of tics, our consensus group has made a weak recommendation based on the risk-benefit profile of this medication. Treatment with haloperidol requires monitoring for EPSs. The consensus group recommends keeping dosages of haloperidol to less than 3 mg/day to minimize side effects.
Fluphenazine. One single-blind, placebo-controlled crossover study, comparing fluphenazine with haloperidol, trifluoperazine, and placebo, has been performed. 15 This study included 10 patients, aged 12 to 43 years, and used dosages of fluphenazine of 8 to 24 mg/day. The study authors reported that in comparison to placebo, all 3 drugs produced statistically significant improvements in tics (numerical data not provided), and none of the 3 proved to be more efficacious than any other. They reported that fluphenazine was the least likely to produce side effects, and that haloperidol was associated with significantly higher rates of sedation and EPSs than fluphenazine and trifluoperazine.
There is 1 open-label study of fluphenazine in 21 patients, aged 7 to 47 years, during a 5-year period. 16 All patients had been intolerant to previous haloperidol treatment. Dosages of fluphenazine ranged from 2 to 15 mg/day. Among the 21 patients, 16 reported fewer side effects with fluphenazine, compared with haloperidol, and they experienced greater or similar improvement in their tics.
Recommendation Grade for Fluphenazine: Weak Recommendation, Low-Quality Evidence. Treatment with fluphenazine requires monitoring for EPSs. The evidence and clinical experience suggest that fluphenazine has fewer adverse effects than haloperidol.
Metoclopramide. One fair-quality RCT of metoclopramide for tics has been conducted. 17 This study randomized 28 children, aged 7 to 18 years, to placebo or metoclopramide at a dose of 5 to 40 mg/day for 8 weeks. The study reported a 38.7% decrease in the YGTSS total tic score with metoclopramide, compared with a 12.6% decrease with placebo (P = 0.001). Weight gain was not different between groups, and there were no EPSs. Three of 14 metoclopramide-treated subjects reported increased appetite and sedation.
Recommendation Grade for Metoclopramide in Children and Adolescents: Weak Recommendation, Low-Quality
Evidence. Recommendation Grade for Metoclopramide in Adults: Category X1, No Specific Recommendation. As none of the members of the consensus group had clinical experience using metoclopramide for the treatment of tics in children or adults, the recommendations are based on the one research study presented. We are unable to make a recommendation on the use of metoclopramide in adults, as there are no data on adult treatment. Members of the consensus group expressed concerns about the use of this medication for tic suppression, as chronic use of metoclopramide for the treatment of gastrointestinal disorders, both in children and in adults, has been associated with severe, treatment refractory, tardive dyskinesia, [18] [19] [20] as well as parkinsonism. 21 Risperidone. Five RCTs of fair quality have assessed risperidone for the treatment of tics: 2 compared risperidone to pimozide, 10,11 2 compared risperidone to placebo, 22,23 and 1 compared risperidone to clonidine. 24 These five studies included a total of 175 patients, aged 6 to 62 years, with mean dosages of 1.5 to 3.8 mg/day. All trials reported an improvement in tics with risperidone. Trials comparing risperidone to pimozide and risperidone to clonidine found similar benefits with each treatment.
Scahill et al 22 compared risperidone with placebo in an RCT of 8 weeks in 34 participants. Subjects treated with risperidone experienced a 32% (8.4 point) decrease in their YGTSS total tic scores, while the placebo group's scores decreased by 7% (P = 0.002). Weight gain was significantly higher with risperidone (2.8 kg, compared with no change, P < 0.001). EPSs were neither reported nor observed. Two children on risperidone developed acute social phobia, and 2 adult males developed erectile dysfunction. Dion et al 23 compared risperidone with placebo in an RCT of 8 weeks in 48 participants. Among risperidone-treated participants, 60.8% improved by at least 1 point on the 7-point Global Severity Rating of the Tourette Syndrome Severity Scale, compared with 26.1% of placebo-treated participants (P = 0.04). Subjects taking risperidone had a significantly higher total score for parkinsonism on the Extrapyramidal Symptom Rating Scale, as well as significantly higher rates of fatigue and somnolence. There was also a trend for a higher rate of depression in the risperidone group (26.1%, compared with 4.4%, P = 0.10).
Recommendation Grade for Risperidone: Weak Recommendation, High-Quality Evidence. While there is high-quality evidence that risperidone is efficacious in suppressing tics, we have made a weak recommendation based on the risk-benefit profile of this medication. Risperidone treatment requires monitoring for EPSs and metabolic side effects. 1 Aripiprazole. There are 5 prospective, open-label studies on the use of aripiprazole for tics in youth. [25] [26] [27] [28] [29] These studies include a total of 138 patients, aged 6 to 19 years, taking a mean daily dosage of 3.3 to 9.8 mg/day. Each study reported a significant improvement in total tic severity on the YGTSS from baseline to end point, and meta-analysis of all 5 studies revealed a mean decrease of 14.9 points (95% CI -16.4 to -13.3, P < 0.001). Significant improvements were usually seen by the second or third week of treatment. The most common adverse effects reported were nausea, sedation, and EPSs. No significant changes in BMI or lipids were reported, though weight gain was reported in some studies. There are 2 case series of aripiprazole for tics in adults, 30, 31 both reporting benefit.
Recommendation Grade for Aripiprazole: Weak Recommendation, Low-Quality Evidence. Currently, there is consistent evidence from open-label studies that aripiprazole is efficacious for the treatment of tics. An RCT is under way on the pediatric use of aripiprazole for tics, so we expect higher-quality evidence will soon be available. Aripiprazole was given a weak recommendation based on its adverse effect profile. Aripiprazole treatment requires monitoring for metabolic abnormalities and EPSs.
Olanzapine. The use of olanzapine for tics is supported by 3 prospective open-label studies, 32-34 1 nonrandomized single-blind study with a 2-week placebo run-in, 35 and 1 nonrandomized crossover study comparing olanzapine with pimozide. 36 These 5 studies included a total of 50 participants, aged 7 to 54 years. Mean daily dosages ranged from 10 to 15 mg/day. All studies reported a significant decrease in tic severity with olanzapine. Meta-analysis of the 3 studies reporting a change in the YGTSS total tic score, from baseline to end point, revealed a mean decrease of 10.9 points (95% CI -14.2 to -7.6, P < 0.001). All studies reported sedation as a side effect of treatment. Weight gain and increased appetite were also frequently reported, with mean increases of 4 to 5 kg during the 6-to 8-week study periods.
Recommendation Grade for Olanzapine: Weak Recommendation, Low-Quality Evidence.
While there is consistent evidence from open-label studies that olanzapine is effective in suppressing tics, a weak recommendation has been made because of the concerns about significant metabolic side effects associated with this medication. Olanzapine causes the most weight gain among second-generation antipsychotics, and has been associated with increases in BMI and waist circumference, lipids, liver enzymes, and blood sugar. 1 The use of olanzapine requires monitoring for metabolic abnormalities and EPSs.
Quetiapine.
There are 2 open-label studies of quetiapine for the treatment of tics: 1 in youth and 1 in adults. In a study by de Jonge et al, 37 12 adults were treated with quetiapine at a mean dose of 205.8 mg/day for 12 weeks. The YGTSS total tic score was not significantly different between baseline and end point, and all study participants complained of sedation. Mukaddes and Abali 38 treated 12 children and adolescents with quetiapine at a mean dose of 72.9 mg/day for 8 weeks. They reported a decrease in the YGTSS tic plus impairment score from 61.17 points at baseline to 24.17 points at end point (P < 0.001). Sedation was reported as a side effect in 3 of the 12 patients during the first week. There was no significant change in weight from baseline to end point.
Recommendation Grade for Quetiapine: Weak Recommendation, Very
Low-Quality Evidence. The evidence for the use of quetiapine is limited and mixed, with one small negative study in adults, and one small positive study in youth. It is the experience of the consensus group that tic suppression with quetiapine is generally achieved at higher doses, which are not tolerable for many patients. Despite the report of no weight gain in the pediatric trial, multiple pediatric and adult studies of quetiapine for other indications indicate that it carries a significant risk of metabolic side effects, including weight gain and increases in BMI, waist circumference, and lipids. 1 The use of quetiapine requires monitoring for metabolic side effects.
Ziprasidone. One RCT of fair quality has evaluated ziprasidone for the treatment of tics. 39 Twenty-eight youths, aged 7 to 17, were randomized to ziprasidone or placebo for 8 weeks at a mean dose of 28.2 mg/day. Total tic severity on the YGTSS decreased from 27.7 to 16.8 with ziprasidone and from 24.6 to 22.9 with placebo (P = 0.008). The most common adverse event was sedation and one subject developed akathisia.
Recommendation Grade for Ziprasidone in Children and Adolescents: Weak Recommendation, Low-Quality Evidence. Recommendation Grade for Ziprasidone in Adults: Category X1, No Specific Recommendation.
Currently, there are no data on the use of ziprasidone in adults for tics, preventing formal recommendations. The use of ziprasidone requires monitoring for EPSs as well as QT interval prolongation on EKG. 40
Nonantipsychotics for the Treatment of Tics
Online eAppendix 6 lists all included trials of nonantipsychotics and Table 3 summarizes recommendations and suggested dosage ranges.
Clonidine. Six RCTs have evaluated the use of clonidine for tics. Significant improvement in tics with clonidine was found in 1 good-quality study 41 comparing oral clonidine with levetiracetam and 2 poor studies comparing oral clonidine with placebo. 42, 43 These 3 studies examined a total of 72 patients, aged 7 to 48 years. Dosages of clonidine ranged from 3.0 to 5.5 μg/kg/day. One fair study 44 comparing the clonidine patch to placebo in 437 patients (aged between 6 and 18 years) found benefit for tics using 1 to 2 mg clonidine patches administered on a weekly basis. Two additional poor-quality studies 45, 46 failed to show any effect of clonidine on tics. Side effects commonly seen with clonidine include sedation, bradycardia, orthostatic hypotension, and dry mouth, as well as localized skin irritation with the clonidine patch.
The use of clonidine for the treatment of ADHD in children with tics has also been studied, with both tic and ADHD outcomes assessed. Kurlan et al 47 randomized 136 children to clonidine, methylphenidate, clonidine plus methylphenidate, or placebo for 16 weeks. In comparison to placebo, children treated with clonidine had a significant decrease in the YGTSS score (-10.9 points, P = 0.003), and in their ADHD symptoms.
Recommendation Grade for Clonidine: Strong Recommendation, Moderate-Quality Evidence.
There is evidence of moderate quality for the efficacy of clonidine for tics, and our consensus group believes that it has a preferable side effect profile, compared with antipsychotics. Therefore, the recommendation for its use can be applied to most patients in most circumstances without reservation. Patients on clonidine should be monitored for sedation and vital sign abnormalities, including postural changes. Clonidine should not be abruptly discontinued, owing to a risk of rebound hypertension.
Guanfacine. Two
RCTs and 2 open-label studies have evaluated the use of guanfacine for tics. One fair-quality RCT 48 compared guanfacine with placebo in 34 children, aged 7 to 14 years. Doses ranged from 1.5 to 3.0 mg/day. After 8 weeks, the YGTSS total tic score decreased from 15.2 to 10.7 points in the guanfacine group, with no change in the placebo group (P = 0.05). An improvement in ADHD symptoms was also demonstrated. There were no differences in side effects. The only other RCT 49 of guanfacine, which was of poor quality, failed to show a difference between guanfacine and placebo.
Two open-label studies have shown a positive effect of guanfacine on tics. Chappell et al 50 studied 10 youths, aged 8 to16 years, on a daily guanfacine dose of 1.5 mg. There was a significant decrease in the phonic tic score on the YGTSS (12.5 to 7.7, P < 0.02), but no significant change in motor tics. The most common side effects were fatigue, headache, and insomnia. Boon-yasidhi et al 51 studied 25 youths, aged 7 to 16 years, taking a mean dose of guanfacine of 2 mg/day. Significant decreases from baseline were noted in the YGTSS total motor score (10.26 to 6.68 points) and total phonic score (8.84 to 4.95 points) (P < 0.001). Side effects included fatigue, insomnia, irritability, lightheadedness, stomachache, and sleep disturbance.
Recommendation Grade for Guanfacine in Children and Adolescents: Strong Recommendation, Moderate-Quality Evidence. Recommendation Grade for Guanfacine in Adults: Category X1, No Specific Recommendation.
There is evidence of moderate quality that guanfacine is efficacious for tics in youth. Currently, there are no data on the use of guanfacine in adults for tics, preventing formal recommendations. The side effect profile of guanfacine is more favourable than that of antipsychotics. Monitoring of sedation and postural vital signs should occur for patients on guanfacine. Approval from the Health Canada Special Access Program is required to prescribe guanfacine.
Topiramate. One fair-quality RCT examined the effect of topiramate on tics. 52 Twenty-nine patients, aged 7 to 65 years, were studied. The mean daily dose of topiramate was 118 mg. The YGTSS total tic score improved by 14.3 points at study end point with topiramate, compared with 5.0 points with placebo (P = 0.03). No differences were observed in adverse events between groups. 53 Additionally, patients should be warned about the possibility of glaucoma 54 and nephrolithiasis. 53 Baclofen. There is 1 poor-quality RCT 55 of 10 children, aged 8 to 14 years, treated for 4 weeks with baclofen 60 mg/day for tics. The mean Clinical Global Impression Severity score improved modestly with baclofen (-0.5) and worsened modestly with placebo (+0.4), resulting in a significant difference between groups (-0.9; 95% CI -1.7 to -0.1, P = 0.04). While the YGTSS total score decreased 14.7 points with baclofen relative to placebo, this was not statistically significant (P = 0.06). Transient side effects reported during baclofen treatment included constipation, nausea, anxiety, and headache.
One open-label study 56 of 264 youths, aged 6 to 18 years, evaluated baclofen for tics. Patients were treated with a mean dose of 30 mg/day for 4 weeks. Significant decreases were noted in motor (P < 0.02) and vocal (P < 0.02) tics as measured by the YGTSS, although further data were not provided. Six patients experienced sedation and drowsiness.
Recommendation Grade for Baclofen in Children and Adolescents: Weak Recommendation, Very Low-Quality
Evidence. Recommendation Grade for Baclofen in Adults: Category X1, No Specific Recommendation. There is very limited, poor-quality data to support the efficacy of baclofen in the treatment of tics in youth. Further, there are no data on the use of baclofen in adults for tics, preventing formal recommendations.
Botulinum Toxin Injections. One poor-quality RCT compared botulinum toxin injections with placebo injections for tics in 20 patients, aged 15 to 55 years. 57 The dosage of botulinum toxin used was not stated. The median proportional change in tics, as recorded by blinded observers of 12-minute patient videos, was -39% in the botulinum toxin group and +5.8% in the placebo group. The median net effect was -37% (interquartile range -77% to -15%). Twelve patients in the botulinum toxin group noted weakness of injected muscles, 2 had motor restlessness, 2 had swallowing difficulty, 2 developed new tics that replaced the treated tic, and 1 had an increased urge to tic.
Four open-label studies also examined the effect of botulinum toxin injections on tics. [58] [59] [60] [61] These studies had a total of 90 patients, aged 8 to 84 years. Doses of botulinum toxin ranged from 2.5 to 300.0 units. Most studies used a 0 to 4 response rating of peak effect, with 65% to 100% of patients showing improvement in motor tics, phonic tics, or both. Forty-five patients experienced side effects, including ptosis, weakness, dysphagia, hypophonia (associated with injections for vocal tics), loss of facial expression, and development of a new tic.
Recommendation Grade for Botulinum Toxin Injections:
Weak Recommendation, Low-Quality Evidence. While the consensus group believes that botulinum toxin injections are generally safe and without systemic side effects, we recommend using this treatment in only very specific situations. Botulinum toxin injections should be considered for the treatment of severely disabling vocal tics, such as coprolalia, or very distressing motor tics involving the upper face or neck. Further, only an experienced clinician should administer botulinum toxin injections.
Tetrabenazine. One open-label study examined tetrabenazine for the treatment of tics. 62 Nine patients, aged 10 to 48 years, were treated with tetrabenazine 25 to 150 mg/day, and the outcomes were measured by the Jankovic hyperkinesia rating scale and family member report. Four patients had sustained improvement on tetrabenazine, with benefits lasting for more than 6 months, while 3 had improvement for less than 6 months. Eight patients experienced side effects, including drowsiness, nervousness, oculogyric crises, depression, nausea, tremulousness, parkinsonism, and insomnia.
Recommendation Grade for Tetrabenazine: Weak Recommendation, Very Low-Quality Evidence. Data regarding the efficacy of tetrabenazine are limited to one small open-label trial. If tetrabenazine is to be used, care should be made to monitor for side effects, including EPSs, depression, anxiety, and hypotension. Death due to pneumonia has been described with the use of this medication. 63, 64 Cannabinoids. Two poor-quality RCTs 65, 66 examined the effect of cannabinoids on tics. Both studies were included in a Cochrane review 67 that received an AMSTAR score of 8 (out of 11). A total of 28 patients, aged 18 to 69 years, were studied. The dosage range of delta-9-THC was 5 to 10 mg/day. Both trials reported a positive effect from THC, although the improvements in tic frequency and severity were small and detected only by some outcome measures.
No serious adverse events were reported. Five patients in the THC group reported tiredness, dry mouth, and dizziness.
Recommendation Grade for Cannabinoids in Children and Adolescents: Category X, Level 2, Not Recommended. Recommendation Grade for Cannabinoids in Adults: Weak Recommendation, Low-Quality Evidence.
There is no evidence to support the use of cannabinoids for the treatment of tics in children or adolescents. Given this lack of evidence, as well as concerns about potential misuse, we do not recommend that cannabinoids be used for treating tics in youth. However, there is low-quality evidence that cannabinoids have modest benefits in the treatment of tics in adults.
The consensus group recommends against the use of levetiracetam, 68,69 intravenous immune globulin, 70 mecamylamine, 71 fluoxetine, 72 and ondansetron 73 for the treatment of tics, as evidence suggests that these treatments are ineffective.
There was insufficient evidence to make formal recommendations on the use of ropinirole, 74 naloxone, 75 naltrexone, 76 adjunctive nicotine, 77, 78 ningdong granule, 79, 80 nifedipine, 81 flunarizine, 81 and nicardipine 82 for the treatment of tics. While there is some literature evaluating the use of these agents to treat tics, the judgment of the consensus group was that further study is required to enable formal recommendations.
There was insufficient evidence to make formal recommendations on the use of flutamide, 83 lecithin, 84 physostigmine, 85 citalopram, 86 fluvoxamine, 86 and propranolol 87 for the treatment of tics. While limited studies of these agents exist, the judgment of the consensus group was that further research on their use for treating tics is not warranted because of concerns about potential worsening of tics, unacceptable adverse events, or poor scientific rationale to support further study.
Discussion
While evidence supports the efficacy of numerous medications for treating tics, most available agents have the potential to cause significant adverse events, causing us to downgrade recommendations to the weak category. With a weak recommendation, the benefits are closely balanced with the risks and side effects. In situations where tics are not severe or disabling, the use of a medication with only a weak recommendation is not warranted. However, when tics are more distressing and interfering, the need for tic suppression to improve quality of life is stronger, and patients and clinicians may be more willing to accept the risks of pharmacotherapy.
Among the available treatment options, our consensus group determined that behavioural therapy (see companion In Review article 7 ) clonidine, and guanfacine should be considered first-line therapies for tics. Botulinum toxin injection was also considered a first-line therapy in adult patients to target severe motor tics affecting the eyes or face, or severe vocal tics, such as coprolalia. Risperidone and aripiprazole are second-line therapies. Pimozide, fluphenazine, haloperidol, and ziprasidone are considered third-line therapies. In children with a comorbid diagnosis of ADHD, the use of clonidine or guanfacine for tics is favoured, as evidence supports their efficacy for treating ADHD symptoms as well. 47, 48 For people who are overweight at baseline, we recommend avoiding olanzapine, quetiapine, and risperidone because of the risk of further weight gain with these medications. 1 Before starting therapy, patients should be informed that medications only suppress tics in the present, and do not alter the natural history of the disorder. Tic severity typically decreases during adolescence, with nearly three-quarters of patients reporting that their tics are greatly diminished by adulthood. 88 Given this natural history of tic disorders, medications should be tapered periodically to determine if the treatment is still required.
This guideline synthesizes the current evidence on the treatment of tics, and provides recommendations based on the evidence while incorporating clinical expertise. We are limited by the strength of the available evidence; many of the trials are small, and include clinically heterogeneous samples. The ability of clinicians to predict which treatment has the greatest chance of success for a given patient is limited. Further large-scale clinical trials comparing the effectiveness of different treatment regimens are likely to be helpful in improving the care of people with tic disorders.
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